| US 7,560,250 B2 | ||
| Soluble fusion proteins comprising heterologous polypeptides | ||
| Nathan Nelson, Tel Aviv (Israel); Anat Lavi, Tel Aviv (Israel); and Shani Leviatan, Mishmar HaSharon (Israel) | ||
| Assigned to Ramot At Tel Aviv University Ltd., Tel-Aviv (Israel) | ||
| Filed on Feb. 12, 2007, as Appl. No. 11/705,106. | ||
| Application 11/705106 is a continuation in part of application No. PCT/IL2005/000874, filed on Aug. 11, 2005. | ||
| Claims priority of provisional application 60/600363, filed on Aug. 11, 2004. | ||
| Prior Publication US 2007/0202573 A1, Aug. 30, 2007 | ||
| Int. Cl. C07K 19/00 (2006.01); C12N 15/62 (2006.01); C12N 15/70 (2006.01); C12N 15/31 (2006.01) | ||
| U.S. Cl. 435—69.7 [530/350; 536/23.4] | 46 Claims |
| 1. A soluble fusion protein comprising at least one soluble polypeptide and a heterologous polypeptide being fused thereto,
said heterologous polypeptide being normally insoluble and/or suboptimally expressed when expressed in an Escherichia coli (E. coli) cell,
wherein said at least one soluble polypeptide has an amino acid sequence at least 65 percent similar to SEQ ID NO: 1, as determined
using the Standard protein-protein BLAST [blastp] software of the NCBI.
|